Simone Susanne Krebs, M.D., M.S.
Department of Nuclear Medicine, Division of Diagnostic Imaging
Present Title & Affiliation
Primary Appointment
Regular Faculty Member, Department of Therapeutics and Pharmacology Program, Division of Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center & UT Health Houston, Houston, TX
Regular Faculty Member, Department of Medical Physics and Therapeutics and Pharmacology Programs, Division of Graduate School of Biomedical Sciences, The University of Texas MD Anderson Cancer Center & The University of Texas Health, Houston, Texas
Associate Professor, Department of Nuclear Medicine, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas
Associate Professor (Joint Appointment), Department of Imaging Physics, Division of Diagnostic Imaging, The University of Texas MD Anderson Cancer Center, Houston, Texas
Licenses & Certifications
| 2024 | Texas Medical Board License |
| 2023 | New Jersey Licensure |
| 2017 | New York Licensure |
| 2017 | American Board of Nuclear Medicine |
Honors & Awards
| 2025 | Featured Article of Month, Journal of Nuclear Medicine |
| 2024 | Saul Hertz Young Investigator Award, 7th Theranostics World Congress |
| 2023 | Leadership Academy, Society of Nuclear Medicine and Molecular Imaging |
| 2022 | 1st Place prize in Basic Track, Society of Nuclear Medicine and Molecular Imaging |
| 2021 | One To Watch, Society of Nuclear Medicine and Molecular Imaging |
| 2021 | EANM Springer Prize 2020 - EJNMMI Best Paper 2020 for the manuscript entitled “Biodistribution and radiation dose estimates for 68Ga-DOTA-JR11 in patients with metastatic neuroendocrine tumors”, European Association of Nuclear Medicine/ European Journal of Nuclear Medicine and Molecular Imaging |
| 2021 | NIH R37 (MERIT) Award, National Institutes of Health |
| 2020 | NIH SPORE Lymphoma Career Enhancement Program Award, National Institutes of Health |
| 2018 | Larry E. Kun, MD Award of Academic Excellence and Dedication to Cures, TeamConnor Childhood Cancer Foundation |
| 2016 | NIH K30 Clinical Research Methodology Curriculum, National Institutes of Health |
| 2016 | NIH K12 Paul Calabresi Career Development Award for Clinical Oncology Program, National Institutes of Health |
| 2015 | Best Poster – Travel Grant for “First in-Human Trial of Dasatinib-Tracer PET Imaging: Preliminary Results in Cancer Patients”, American College of Nuclear Medicine and Society of Nuclear Medicine and Molecular Imaging |
| 2008 | Federation of European Neuroscience Societies (FENS) Award |
Selected Publications
Peer-Reviewed Articles
- Hegde M, Mukherjee M, Grada Z, Pignata A, Landi D, Navai SA, Wakefield A, Fousek K, Bielamowicz K, Chow KK, Brawley VS, Byrd TT, Krebs S, Gottschalk S, Wels WS, Baker ML, Dotti G, Mamonkin M, Brenner MK, Orange JS, Ahmed N. Tandem CAR T cells targeting HER2 and IL13Ralpha2 mitigate tumor antigen escape. J Clin Invest 129(8):3464, 2019. e-Pub 2019. PMID: 31264975.
Abstracts
- Imber B, Jackson C, Young R, Humm J, Grkovski M, Bale T, Miller A, Mellinghoff I, Krebs S, Schoder H, Kaley T. A prospective phase I study of adjuvant [177Lu]Lu-PSMA-617 for PSMA-expressing IDH wildtype gliomas following chemoradiotherapy. Nuclear Medicine and Neurooncology Symposium: Precision Medicine:46, 2025. e-Pub 2025.
- Jenabi M, Pasquini L, Gunjan Shah, Mailankody S, Scordo M, Landau H, Rajeeve S, Lesokhin S, Hashmi H, Perica K, Hultcrantz M, Korde N, Shah U, Tan C, Hassoun H, Usmani S, Giralt S, Santomasso B, Holodny A, Krebs S. Investigating metabolic connectivity in patients with multiple myeloma receiving BCMA CAR T cell therapy. American Society of Clinical Oncology Annual Meeting 43(16_Suppl):7524, 2025. e-Pub 2025.
- Imber B, Kwok Hei Yu K, Abida W, Pike L, Grkovski M, Kaley T, Morris M, Bodei L, Nosov A, Dunphy M, Schoder H, Fox J, Rosenblum M, Bale T, Krebs S. Symptomatic prostate-specific membrane antigen (PSMA) PET-positive radionecrosis following multimodality brain metastasis-directed treatment including [177Lu]Lu-PSMA-617. Nuclear Medicine and Neurooncology Symposium: Precision Medicine:29, 2025. e-Pub 2025.
- Mirzaei HR, Lovibond S, Gajecki L, Qureshy S, Kumpf M, Jeanjean P, Lee SG, Cai W, Miranda I, Mauguen A, Carter L, Schöder H, Veach DR, Scheinberg DA, Krebs S. Longitudinal in vivo tracking of novel human anti-IL13Rα2-scFv-derived CAR-T cells using radiohapten capture. Preclinical Imaging Consortium, 2025. e-Pub 2025.
- Qureshy S, Gajecki L, Veach D, Lee SG, Matei I, Carter L, Lyden D, Scheinberg D, Krebs S. Utilizing CAR T cell-derived exosomes for radiotheranostic applications. American Association for Cancer Research Annual Meeting 85(8_Suppl_1):Abstract nr 585, 2025. e-Pub 2025.
- Qureshy S, Gajecki L, Veach D, Matei I, Lee SG, Carter, Lyden D, Scheinberg D, Krebs S. Engineering CAR T Cell Exosomes for Tumor-Specific Delivery of Imaging and Therapeutic Radionuclides. European Molecular Imaging Meeting, 2025. e-Pub 2025.
- Jeanjean P, Kumpf M, Lovibond S, Gajecki L, Veach DR, Krebs S. Interleukin-13 Receptor Alpha 2-targeted ImmunoPET in Sarcoma. European Molecular Imaging Meeting, 2025. e-Pub 2025.
- Gajecki, L, Lebedeva I, Ambriz D, Lovibond S, Veach D, Jungbluth A, Carter L, Schoder H, Larson S, Krebs S. Novel IL13Rα2-targeting antibodies for immunoPET in glioblastoma. European Molecular Imaging Meeting, 2024. e-Pub 2024.
- Eibler L, Kurtz KG, Dacek MM, Carter LM, Lovibond S, Reynaud E, Veach DR, Qureshy S, McDevitt MR, Bourne C, Monette S, Punzalan B, Khayat S, Verma S, Cheung NK, Kesner AL, Schöder H, Cheal SM, Scheinberg DA, Larson SM, Krebs S. A novel image-guided CAR T-cell approach for delivery of α-radionuclides to enhance anti-tumor killing efficacy in lymphoma. European Molecular Imaging Meeting, 2023. e-Pub 2023.
- Kurtz K, Eibler L, Dacek M, Carter LM, Cheal S, Veach DR, Qureshy SA, Han J, Reynaud E, Verma S, McDevitt M, Punzalan B, Vargas DB, Santich BH, Monette S, Kesner A, Cheung NK, Larson S, Scheinberg DA, Krebs S. A radiohapten capture system for CAR T cells that tracks them in vivo and improves efficacy. 34th EORTC-NCI-AACR Symposium 174(Suppl 1):S3, 2022. e-Pub 2022.
- Eibler L, Kurtz K, Dacek M, Carter L, Cheal S, Veach D, Qureshy S, Han J, Reynaud E, Verma S, McDevitt M, Punzalan B, Burnes Vargas D, Santich B, Monette S, Kesner A, Cheung N-K, Scheinberg D, Larson S, Krebs S. A humanized anti-benzyl-DOTA single chain variable fragment for in vivo tracking of CD19 CART cells. Society of Nuclear Medicine and Molecular Imaging Annual Meeting 63(Suppl 2), 2022. e-Pub 2022.
- Krebs S. Comparison of 68Ga-DOTA-JR11 PET/CT with Dosimetric 177Lu-satoreotide Tetraxetan (177Lu-DOTA-JR11) SPECT/CT in Patients with Metastatic Neuroendocrine Tumors Undergoing Peptide Receptor Radionuclide Therapy. Third International Conference on Medical Imaging and Case Reports 6(1):S4, 2022. e-Pub 2022.
- Dacek M, Cheal S, Veach D, Qureshy S, Carter L, Eibler L, Verma S, Mcdevitt M, Punzalan B, Burnes Vargas D, Santich B, Kesner A, Cheung N-K, Scheinberg D, Larson S, Krebs S. Characterization of a novel radiohapten capture system in CAR T cells for tracking in vivo and improving CAR T efficacy. International Conference on Lymphocyte Engineering 33(7-8):A6, 2022. e-Pub 2022.
- Eibler L, Kurtz KG, Dacek MM, Carter LM, Cheal SM, Veach DR, Qureshy S, Han J, Reynaud E, Verma S, McDevitt MR, Punzalan B, Burnes Vargas D, Santich BH, Monette S, Kesner AL, Cheung NK, Scheinberg DA, Larson SM, Krebs S. Optimizing a humanized DOTA single chain variable fragment reporter platform for in vivo CAR T cell tracking. European Molecular Imaging Meeting, 2022. e-Pub 2022.
- Dacek MM, Kurtz KG, Cheal SM, Veach DR, Qureshy S, Carter LM, Han J, Verma S, McDevitt MR, Punzalan B, Burnes Vargas D, Santich BH, Kesner AL, Cheung NK, Scheinberg DA, Larson SM, Krebs S. Assessing the impact of structural differences in CAR T Cell reporter gene design on performance. World Molecular Imaging Congress, 2021. e-Pub 2021.
- Krebs S, Graham MS, Grkovski M, Mauguen A, Goel R, Thakur SB, Schaf LR, Mellinghof IK, Young RJ, Kaley T, Dunphy MP. 18F-Fluoroglutamine PET as a Promising Prognostic Tool in IDH Mutant Glioma. Annual Congress of the European Association of Nuclear Medicine 48(Suppl 1):S298, 2021. e-Pub 2021. PMID: 34559267.
- Krebs S, Dacek MM, Cheal SM, Veach DR, Carter LM, Verma S, Santich B, Punzalan B, Burnes Vargas D, Kesner AL, Cheung NK, Scheinberg DA, Larson SM. Cell surface-anchored humanized anti-DOTA scFv for tracking CD19 CAR T cells. World Molecular Imaging Conference Virtual, 2020. e-Pub 2020.
- Krebs S, O'Donoghue J, Biegle E, Beattie BJ, Reidy D, Bodei L, Weber WA, Pandit-Taskar N. Comparison of 68Ga-DOTA-JR11 PET/CT with (dosimetric) 177Lu-DOTA-JR11 SPECT/CT in patients with metastatic neuroendocrine tumors undergoing peptide receptor radionuclide therapy. Annual Congress of the European Association of Nuclear Medicine 45(Suppl 1):S63-S64, 2018. e-Pub 2018.
- Krebs S, Dunphy M, Humm J, Chaft J, Fredrickson J, Weber WA. Delayed 18F-FDG PET imaging can improve detection of lesions in patients with advanced non-small cell lung cancer. Annual Congress of the European Association of Nuclear Medicine 43(Suppl 1):S309, 2016. e-Pub 2016.
- Krebs S, Dunphy M, Hyman D, Fornier M, Veach D, Larson S, Lyashchenko S, Zanzonico P, Lewis J, Weber WA. First-in-human trial of dasatinib-tracer PET imaging: preliminary results in cancer patients. ACNM Annual Meeting and SNMMI Mid-Winter Meeting, 2015.
- Krebs S, Chow K, Yi Z, Brawley V, Ahmed N, Gottschalk S. T cells expressing IL13Rα2-specific chimeric antigen receptors based on IL13.E13K Muteins have potent anti-glioma activity but also recognize IL13Rα1+ cells. Pediatric Neuro-Oncology Basic and Translational Research Conference 15(Suppl):i1-i51, 2013. e-Pub 2013.
- Krebs S, Chow K, Yi J, Brawley V, Ahmed N, Gottschalk S. T cells redirected to IL13Rα2 for glioblastoma immunotherapy. 3rd International Conference on Immunotherapy in Pediatric Oncology, 2012.
- Krebs S, Trippel M, Prokop T, Omer TN, Landwehrmeyer B, Weber WA, Nikkhah G. Immune response after cerebral engraftment of human neuronal cells in patients with Huntington's disease. 20th Annual Meeting of the Network of European CNS Transplantation and Restoration, 2010.
- Krebs S, Trippel M, Prokop T, Omer TN, Landwehrmeyer B, Weber WA, Nikkhah G. Immune response after cerebral engraftment of human neuronal cells in patients with Huntington's disease: Consequences for pediatric neuronal cell transplantation programs. 2nd International Conference on Immunotherapy in Pediatric Oncology, 2010. e-Pub 2010.
- Krebs S, Trippel M, Prokop T, Omer TN, Landwehrmeyer B, Weber WA, Nikkhah G. HLA-antibodies after intrastriatal engraftment of human foetal neuronal cells in patients with Huntington's disease: Clinical course and consequences for immunosuppressive therapy. 10th Meeting of the Forum of European Neurosciences, 2008.
Patient Reviews
CV information above last modified August 19, 2025